NAFLD impacts 25% of the global population1
Because of the increasing global burden of non-alcoholic fatty liver disease, lack of appropriate non-invasive testing options is a major concern.
The ELF Test is a non-invasive blood test that measures three direct markers of fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The ELF Test, in conjunction with other laboratory and clinical findings, can be used to assess the risk of progression to cirrhosis and LREs in patients with chronic liver disease.
Convenient, objective, reproducible, and widely available to all relevant healthcare practitioners.
This compendium highlights a small subset of the extensive number of ELF publications and provides an introduction to the ELF Test.
The performance of the ELF Test for assessing risk of progression to cirrhosis and LREs has been well-established in scientific literature, and ease of testing and interpretation support routine clinical use to complement biopsy.